stockrow
Friday 6 November 2026
Export CLDX’s income statement to Excel — free account
Celldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
29.90
1.63
+5.77%
Follow CLDX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 663.24 | 1,353.51 | 3,265.42 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (28.21) | (32.19) | (50.45) | |
P/B ratio |
— | 3.42 | 4.63 | 4.05 | |
Price to Tangible BV |
— | 3.61 | 4.92 | 4.21 | |
EV/Sales |
— | 473.52 | 1,065.73 | 2,459.26 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (6.11) | (7.48) | (9.26) | |
EV/FCF |
— | (6.03) | (7.35) | (9.01) | |
Quick Ratio |
12.55 | 10.21 | 8.78 | 11.71 | |
Current Ratio |
13.01 | 10.49 | 8.92 | 11.82 | |
Net Debt/EBITDA |
7.90 | 5.93 | 5.36 | 8.80 | |
Debt/Assets |
0.00% | 0.21% | 0.00% | 0.16% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.79 | 0.83 | 0.78 | |
Capex/Depreciation |
2.27 | 19.41 | (7.32) | 3.99 | |
Research and Development Expense of Revenue |
0.00% | 62,777.50% | 486,673.33% | 307,009.09% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 9,950.83% | 76,326.67% | 59,559.09% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.05 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 7,424.17% | 56,820.00% | 38,218.18% | |
Graham Net Nets |
— | 0.27 | 0.19 | 0.23 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (14.32%) | (13.43%) | (11.69%) | |
Free Cash Flow Yield |
— | (11.84%) | (10.72%) | (8.36%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.73) | (0.96) | (0.99) | (0.74) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.04) | |
Free Cash Flow per Share |
(0.74) | (0.98) | (1.01) | (0.78) | |
Cash per Share |
8.78 | 7.81 | 6.78 | 9.22 | |
Shareholders Equity per Share |
9.01 | 7.94 | 6.85 | 9.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.01 | 7.94 | 6.85 | 9.18 | |
Free Cash Flow |
(49.07) | (65.22) | (67.23) | (60.59) | |
Working Capital |
557.87 | 483.67 | 407.75 | 663.61 | |
Capital Expenditures |
(0.44) | (1.28) | (1.64) | (3.18) | |
Net Current Asset Value |
554.26 | 478.85 | 404.19 | 657.15 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 10.68 | 109.27 | 144.50 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.47 | 1.36 | 0.65 | 0.16 | |
Average Payables |
2.69 | 2.22 | 6.88 | 8.37 | |
Average Assets |
735.81 | 687.66 | 625.36 | 737.38 | |
Average Common Equity |
692.13 | 637.08 | 579.60 | 684.99 |
Columns are period end dates